Who Attended in 2023:

Thank You to Our Speakers, Sponsors, and Delegates Who Joined Us in June for the Summit! If You Are Interested in the 2024 Event, Please Get in Touch by Clicking the Button Below:

Innovating Imaging Measures of Disease Progression & Improvement to Determine Drug Efficacy Sooner

June 13 - 15, Boston MA

Welcome to the Definitive Industry Forum for Advancing Imaging Biomarkers to Accelerate Retinal Drug Development

Uniting biotech and pharma scientists to revolutionize ophthalmic drug development, the Retinal Imaging Biomarkers & Endpoints Summit encouraged forward-thinking discussions to enhance the adoption of novel imaging-based approaches to determine retinal function and optimize development of regulatory accepted endpoints.

60+ retinal imaging, innovation, R&D, preclinical and clinical experts from the likes of Genentech, AbbVie, Apellis, Janssen and Novartis came together to overcome the translational challenges of choosing and implementing novel ophthalmic imaging biomarkers and endpoints in your research, to accelerate earlier, non-invasive and personalised healthcare for ophthalmic and neurodegenerative patients.

A Snapshot of 2023’s World-Class Speaker Faculty:

Alex McKeown

Senior Director - Translational Ophthalmology & Research


Guillaume Normand

Director - Clinical Development


Jing Hua

Director - Clinical Development & Med Affairs

Boehringer Ingelheim

Kamal Dhakal

Senior Scientist I


Victor Chong

Vice President & Global Head of Retina


“Looking forward to discussing with other drug developers how we can harness cutting-edge imaging technologies to improve endpoints in our clinical trials.”
Guillaume Normand, Director of Clinical Development, Novartis

2023 Partners:

Other Events in the World CNS Series